The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex’s innovative FDA approved non-opioid therapies and pipeline candidate products. The certification is an important prerequisite for health care and covers health and wellness as Read More

PALO ALTO, Calif. , March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

PALO ALTO, Calif. , March 05, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, Read More

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States 1 . Read More

Redesigned website reflects the Company's expanded pipeline of non-opioid pain management products and links to its recent publications and news PALO ALTO, Calif. , March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating Read More

PALO ALTO, Calif. , March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Read More

PALO ALTO, Calif. , Feb. 29, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, Read More

Leading national pharmacy chain to stock GLOPERBA ® in majority of their stores throughout the U.S.  Scilex is also in the process of negotiating similar potential stocking arrangements with additional pharmacy chains in the U.S. For its potential launch expected in the first half of 2024, GLOPERBA Read More

PALO ALTO, Calif. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More

PALO ALTO, Calif. , Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today Read More